XML 44 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities    
Net loss $ (51,898) $ (35,195)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 321 382
Amortization of right-of-use assets, operating leases 857 788
Amortization of debt discount 75 0
Non-cash interest expense 232 1,061
Costs expensed upon the issuance of warrants 549 0
Change in fair value of embedded derivative 0 (429)
Change in fair value of warrant liability 3,886 2
Loss on issuance of warrants 3,502 0
Stock-based compensation 1,452 1,179
Non-cash professional services expense 0 75
Gain on extinguishment of promissory notes 0 (605)
(Gain) loss on disposal of property and equipment (3) 105
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 835 (729)
Other long-term prepaid assets 2,233 0
Accounts payable (3,331) 23
Accrued expenses 4,658 2,216
Deferred research obligation 475 (742)
Operating lease liability (911) (825)
Net cash used in operating activities (37,068) (32,694)
Cash flows from investing activities    
Purchases of property and equipment (87) (66)
Proceeds from sale of property and equipment 3 34
Net cash used in investing activities (84) (32)
Cash flows from financing activities    
Cash acquired in connection with the reverse merger 0 24,001
Merger transaction costs 0 (2,364)
Proceeds from issuance of promissory notes payable 0 10,000
Proceeds from issuance of common stock warrants from March PIPE 5,985 0
Proceeds from issuance of common stock warrants from July Public Offering 11,484 0
Proceeds from issuance of common stock 4,555 6,999
Proceeds from issuance of common stock from July Public Offering 1,080 0
Payment of warrant issuance costs (549) 0
Proceeds from issuance of senior note, net of issuance costs 19,727 0
Payment of employee withholding taxes on restricted stock 0 (150)
Proceeds from exercise of stock options 39 127
Net cash provided by financing activities 42,321 38,613
Effect of foreign currency on cash 22 0
Net increase in cash, cash equivalents and restricted cash 5,191 5,887
Cash, cash equivalents and restricted cash at the beginning of the year 14,301 8,414
Cash, cash equivalents and restricted cash at the end of the year 19,492 14,301
Components of cash, cash equivalents and restricted cash:    
Cash and cash equivalents 17,618 12,894
Restricted cash 1,874 1,407
Total cash, cash equivalents and restricted cash 19,492 14,301
Fair value of pre-funded warrants at issuance date 13,382 0
Fair value of common warrants at issuance date (6,509) 0
Accretion of promissory note discount from embedded derivative 0 10,027
Accretion of promissory note to face value 26 130
Settlement of promissory notes payable 0 897
Non-cash vesting of restricted common stock 25 67
Non-cash issuance of common stock from conversion of preferred stock 0 111,060
Common Stock | Angion Stockholders    
Non-cash issuance of stock 0 19,526
Common Stock | Service Agreement    
Non-cash issuance of stock $ 0 $ 75